Table 2.
Overview of nephrotoxicity from oncologic drugs
| Renal syndromes associated with AKI or CKD |
| Acute tubular necrosis |
| • Cisplatin |
| • Pemetrexed |
| • Streptozocin* |
| • Mithramycin |
| • Zoledronate |
| Acute interstitial nephritis |
| • Interferon |
| • Allopurinol |
| Thrombotic microangiopathy |
| • Gemcitabine |
| • Mitomycin C |
| • Anti-angiogenic agents |
| Crystal nephropathy |
| • Methotrexate |
| Renal syndromes associated with electrolyte disorders |
| Proximal tubulopathies (often leading to Fanconi syndrome) |
| • Cisplatin |
| • Ifosfamide |
| • Streptozocin* |
| Hyponatremia (from SIADH) |
| • Cyclophosphamide |
| • Vincristine |
| Hypernatremia (from nephrogenic diabetes insipidus) |
| • Cisplatin |
| • Ifosfamide |
| Hypomagnesemia |
| • Cetuximab |
| • Cisplatin |
Note:
*
Streptozocin is also referred to as streptozotocin.
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; SIADH, syndrome of inappropriate antidiuretic hormone secretion.